Iambic Therapeutics, founded in 2019 by Thomas Miller and Fred Manby, is a cutting-edge biopharmaceutical company based in California. The company leverages artificial intelligence (AI) to revolutionize drug discovery and development, aiming to address unmet patient needs by optimizing medicines for specific target profiles. 

Central to Iambic's innovation is its AI-driven platform, which combines physics-based algorithms with high-throughput experimental automation. This integration enables the rapid design and testing of small-molecule therapeutics, converting new molecular designs into biological insights weekly. Notably, their platform has demonstrated the capability to deliver high-quality, differentiated therapeutics to the clinic at an unprecedented pace.